No influence of ABCB1 haplotypes on methadone dosage requirement

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 5, 2008, Pages 668-669

  Crettol, S ^a   Deglon J J ^b   Besson, J ^c   Croquette Krokar, M ^d   Hammig R ^e   Gothuey, I ^f   Monnat, M ^c   Eap, C B ^a  

^a Hopital de Cery   (Switzerland)

^b Fondation Phenix   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e Psychiatrische Universitatsklinik   (Switzerland)

^f Unité Ambulatoire Spécialisée   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE;

DOSE RESPONSE; DRUG MECHANISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LETTER; OPIATE ADDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HAPLOTYPES; HUMANS; METHADONE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 42349092219     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100305     Document Type: Letter

References (4)

1. Coller, J.K., Barratt, D.T., Dahlen, K., Loennechen, M.H. & Somogyi, A.A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin. Pharmacol. Ther. 80, 682-690 (2006).
2. Crettol, S. et al. Methadone enantiomer plasma levels CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593-604 (2005).
3. Crettol, S. et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80, 668-681 (2006).
4. Marzolini, C., Paus, E., Buclin, T. & Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).